Trial Profile
A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics
- 13 Feb 2021 Results presented at the 2021 Genitourinary Cancers Symposium
- 08 Feb 2021 According to a Bayer media release, data from this study will presented at the 2021 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place from 11th Feb to 13th Feb 2021.
- 20 Jul 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Feb 2022.